Q-omics provides the consensus-scored ACTB profile across patient tissues and cancer cell-line models. ACTB expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ACTB is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ACTB protein abundance shows 35,070 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where ACTB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTB survival associations across molecular data types. ACTB RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTB RNA expression–survival associations across cancer types. High ACTB expression shows unfavorable associations in MESO, UVM, HNSC, KICH, ACC and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ACTB RNA expression.
This table summarizes ACTB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ACTB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTB shows lower tumor expression in BLCA and higher tumor expression in HNSC, KIRP, KIRC, LIHC and BRCA. The HNSC box plot shows higher ACTB RNA expression in tumor versus normal tissue (log2 FC = +0.922, t-test p < 0.001).
This table shows molecular features associated with ACTB in patient tissues and cancer cell lines. In patient samples, ACTB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
